Burns E C, Tanner J M, Preece M A, Cameron N
Clin Endocrinol (Oxf). 1981 Jun;14(6):587-95. doi: 10.1111/j.1365-2265.1981.tb02969.x.
Twenty-seven out of thirty craniopharyngioma patients treated with human growth hormone (hGH) for 2 years or more (average 4.5 years) reached final adult heights above the population third centile, though none was above the fiftieth centile. However, only twelve of twenty-eight patients had final heights above the lower limits to be expected from their parents' heights. All patient eventually had long legs relative to sitting height (final mean subischial leg length SDS = + 0.2, final mean sitting height SDS = -3.0). Twenty-nine patients were TSH-deficient, twenty-two were ACTH-deficient, thirteen were deficient in ADH and all had total (85%) or partial (15%) gonadotrophin deficiency. Following the administration of testosterone or hCG the boys had, on average, only half the normal adolescent growth spurt. This may have been due to the lateness of starting androgens in these patients and we recommend, when considering height, that testosterone or hCG should be started when a bone age of 13.0 "years' is reached or when a lower bone age has remained unchanged for a year. The girls showed adolescent height spurt; the average increase after oestrogen treatment commended was 1.7 cm.
30例接受人生长激素（hGH）治疗2年或更长时间（平均4.5年）的颅咽管瘤患者中，27例最终成年身高超过人群第3百分位数，但无一人超过第50百分位数。然而，28例患者中只有12例的最终身高高于根据其父母身高预期的下限。所有患者最终的腿长相对于坐高都较长（最终平均坐骨下腿长SDS = +0.2，最终平均坐高SDS = -3.0）。29例患者促甲状腺激素缺乏，22例促肾上腺皮质激素缺乏，13例抗利尿激素缺乏，所有患者均有完全性（85%）或部分性（15%）促性腺激素缺乏。给予睾酮或人绒毛膜促性腺激素后，男孩的青春期生长突增平均仅为正常水平的一半。这可能是由于这些患者开始使用雄激素的时间较晚，我们建议，在考虑身高问题时，当骨龄达到13.0“岁”或较低骨龄持续一年未变时，应开始使用睾酮或人绒毛膜促性腺激素。女孩出现了青春期身高突增；雌激素治疗开始后的平均身高增加为1.7厘米。
